Literature DB >> 6595185

Study of duodenal ulcer disease in 100 families using total serum pepsinogen as a genetic marker.

C M Habibullah, M Mujahid Ali, M Ishaq, R Prasad, B Pratap, Y Saleem.   

Abstract

Although various markers have been used in attempts to elucidate the mode of inheritance of duodenal ulcer, they have not significantly contributed to a clear understanding of the problem. In the present study total serum pepsinogen was used as a genetic marker and its concentrations were estimated in 100 ulcer patients and their family members up to three generations. Eighty three per cent of the ulcer patients had hyperpepsinogenaemia on a familial basis, and it followed an autosomal dominant mode of inheritance. Thus a large majority of ulcer patients have associated hyperpepsinogenaemia which forms a genetic basis of their disease. The remaining 17% ulcer patients did not have associated hyperpepsinogenaemia nor was the ulcer inherited by the family. Based on these observations we wish to suggest that duodenal ulcer associated with hyperpepsinogenaemia may be considered a genetic disease. This type may be termed 'primary duodenal ulcer'. In the remaining patients without hyperpepsinogenaemia or affected relatives the ulcer may be called 'secondary duodenal ulcer'. Thus total serum pepsinogen may be considered a reliable genetic marker in helping to delineate the genetic disorder from the non-genetic, thereby improving the predictive ability in duodenal ulcer.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6595185      PMCID: PMC1420188          DOI: 10.1136/gut.25.12.1380

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  7 in total

1.  Genetic tests under incomplete ascertainment.

Authors:  N E MORTON
Journal:  Am J Hum Genet       Date:  1959-03       Impact factor: 11.025

2.  Blood plasma pepsinogen. I. The source, properties, and assay of the proteolytic activity of plasma at acid reactions.

Authors:  A MIRSKY; P FUTTERMAN; S KAPLAN; R H BROH-KAHN
Journal:  J Lab Clin Med       Date:  1952-07

3.  Pepsinogen Group I radioimmunoassay and total serum pepsinogen colorimetric determination: a comparative study in normal subjects and in peptic ulcer patients.

Authors:  M Plebani; F Di Mario; F Vianello; A Giordano; M Masiero; M Lazzaretto; R Farini; G Ceriotti; R Naccarato
Journal:  Clin Biochem       Date:  1983-02       Impact factor: 3.281

Review 4.  Peptic ulcer disease--a heterogeneous group of disorders?

Authors:  J I Rotter; D L Rimoin
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

5.  HLA and duodenal ulcer.

Authors:  A Ellis; J C Woodrow
Journal:  Gut       Date:  1979-09       Impact factor: 23.059

6.  Duodenal-ulcer disease associated with elevated serum pepsinogen I: an inherited autosomal dominant disorder.

Authors:  J I Rotter; J Q Sones; I M Samloff; C T Richardson; J M Gursky; J H Walsh; D L Rimoin
Journal:  N Engl J Med       Date:  1979-01-11       Impact factor: 91.245

7.  Genetic heterogeneity of hyperpepsinogenemic I and normopepsinogenemic I duodenal ulcer disease.

Authors:  J I Rotter; G Petersen; I M Samloff; R B McConnell; A Ellis; M A Spence; D L Rimoin
Journal:  Ann Intern Med       Date:  1979-09       Impact factor: 25.391

  7 in total
  3 in total

1.  [Symptomless and complicated peptic ulcer as an extreme clinical form of ulcer disease: consequences for choice between conservative and surgical therapy].

Authors:  W Lorenz; K Thon; C Ohmann; H D Röher
Journal:  Langenbecks Arch Chir       Date:  1985

2.  Serum pepsinogen I concentrations in peptic ulcer patients in relation to ulcer location and stage.

Authors:  Y Tanaka; K Mine; Y Nakai; N Mishima; T Nakagawa
Journal:  Gut       Date:  1991-08       Impact factor: 23.059

3.  Pepsin concentration in gastroduodenal biopsy homogenates in chronic ulcer disease.

Authors:  F Vianello; F Di Mario; M Plebani; B Germana; P Dal Santo; G Leandro; P Dotto; S A Grassi; G Battaglia; R Naccarato
Journal:  Dig Dis Sci       Date:  1994-02       Impact factor: 3.199

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.